Arcutis is a fast-growing, wide-moat biotech with 59% YoY growth and consistent earnings beats, but revenue rides on one product franchise and the stock offers only 6.1% upside to the analyst target against 15% downside ahead of earnings in 3 days.
Thesis pillars
- Rapid Revenue Growth→Stable
- Wide Moat Quality Profile→Stable
- Consistent Earnings Beats↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026, based on the 10-K filed Feb 25, 2026
Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $34.05: Concentration risk — Product: ZORYVE franchise; Concentration risk — Supplier: AstraZeneca.
Arcutis Biotherapeutics is a commercial-stage dermatology company with four FDA-approved ZORYVE products targeting plaque psoriasis, seborrheic dermatitis, and atopic dermatitis in the U.S. and Canada. Revenue derives entirely from ZORYVE net product sales; the company reported... Read more
Sell if holding. Multiple concerning factors at $34.05: Concentration risk — Product: ZORYVE franchise; Concentration risk — Supplier: AstraZeneca. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.4/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Arcutis Biotherapeutics, Inc.
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics holds four FDA-approved ZORYVE products — cream 0.3% for plaque psoriasis (July 2022), foam 0.3% for seborrheic dermatitis (December 2023) and scalp psoriasis (May 2025), cream 0.15% for atopic dermatitis (July 2024), and cream 0.05% for atopic dermatitis in children ages 2 to 5 (October 2025). The company reported a net loss of approximately $16.1 million for the year ended December 31, 2025, with an accumulated deficit of $1,138.1 million. All commercial revenue derives from the ZORYVE franchise sold in the United States and Canada.
Arcutis sells ZORYVE through a dermatologist-focused sales force in the United States and Canada. A promotion agreement with Kowa Pharmaceuticals America, Inc. to market ZORYVE through primary care and pediatric channels was mutually terminated effective January 23, 2026, and the company has since recaptured direct responsibility for that prescribing base. The company estimates an actively prescription-treated patient market of approximately 17.0 million in the U.S. across plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, with roughly 3.7 million of dermatology-office patients covered by Medicare or Medicaid and roughly 4.7 million by private payers. The active pharmaceutical ingredient roflumilast is licensed exclusively from AstraZeneca AB under a 2018 agreement, with patent exclusivity for the cream formulation through 2037 and the foam formulation through 2042.
Show full overview
Arcutis's $100.0 million outstanding Loan Agreement with SLR Investment Corp. at December 31, 2025 requires the company to generate minimum net product revenue equal to 75% of projected net product revenue, tested on a trailing six-month basis each month, with the board-approved annual plan serving as the benchmark. A tranche C-1 term loan of up to $50.0 million expired March 31, 2026 and a tranche C-2 of up to $50.0 million expires June 30, 2026. If ZORYVE revenue growth fails to meet projections, the revenue covenant could trigger an event of default, potentially accelerating debt obligations due August 1, 2029.
See also: Healthcare · Biotechnology
From Arcutis Biotherapeutics, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated Nov 5, 2026Recent Developments — Arcutis Biotherapeutics, Inc.
Latest news
- NEWS Why AppLovin Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket — benzinga Nov 5, 2026 positive
- NEWS Arcutis Director Robert A. Scott Awarded RSUs and Stock Options on October 23, 2026 - Kalkine Media — Kalkine Media Oct 28, 2026 neutral
- NEWS Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance — Yahoo Finance Oct 28, 2026 positive
- NEWS Is Arcutis Biotherapeutics (ARQT) Undervalued After Q2 Earnings - GuruFocus — GuruFocus Aug 5, 2026 positive
- NEWS Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance — Yahoo Finance Aug 5, 2026 positive
Latest item Nov 5, 2026 · Generated 2026-11-05T11:34:06Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductZORYVE franchise10-K Item 1A: 'Our business is dependent on the successful commercialization of ZORYVE and the development, regulatory approval, and commercialization of our current product candidates.'
- HIGHSupplierAstraZeneca10-K Item 1: 'we executed a licensing agreement with AstraZeneca AB (AstraZeneca) for exclusive worldwide rights to roflumilast as a topical product in humans solely for dermatological indications'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $34.05: Concentration risk — Product: ZORYVE franchise; Concentration risk — Supplier: AstraZeneca. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $31.67. Score 6.4/10, moderate confidence.
Analyst target $34.04 reached (0.0% from $34.05); no take-profit level is published. Prior stop was $31.67. Stop-loss: $31.67.
Concentration risk — Product: ZORYVE franchise; Concentration risk — Supplier: AstraZeneca; Analyst target reached - limited upside remaining.
Arcutis Biotherapeutics, Inc. trades at a P/E of 154.8 (forward 25.4). TrendMatrix value score: 4.6/10. Verdict: Sell.
14 analysts rate ARQT, with a consensus score of 4.1/5. 8 analysts publish price targets averaging $39.
What does Arcutis Biotherapeutics, Inc. do?Arcutis Biotherapeutics is a commercial-stage dermatology company with four FDA-approved ZORYVE products targeting...
Arcutis Biotherapeutics is a commercial-stage dermatology company with four FDA-approved ZORYVE products targeting plaque psoriasis, seborrheic dermatitis, and atopic dermatitis in the U.S. and Canada. Revenue derives entirely from ZORYVE net product sales; the company reported a net loss of approximately $16.1 million for 2025 against an accumulated deficit of $1,138.1 million at December 31, 2025.